The product designated VetADG-1024 is released under the name Antigen Detection Kit Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions. It is a lyophilised colloidal gold conjugate intended for downstream incorporation into solid oral, parenteral, and feed-based diagnostic formats. The active component consists of a monoclonal capture antibody raised against conserved surface antigen epitopes, conjugated to 40 ± 5 nm gold nanoparticles and stabilised in a trehalose dihydrate matrix at a 5:1 excipient-to-antibody mass ratio. Each single-use Type I borosilicate vial contains 10.0 mg of lyophilised cake with a mean cake height of 4.2 mm. The closure is bromobutyl rubber with a laminated polytetrafluoroethylene barrier. The material is produced for veterinary diagnostic manufacturers and feed-testing laboratories, not for direct animal administration unless formulated into a registered dosage form by the receiving facility.

Batch release specifications include residual moisture of ≤ 5.0% w/w by Ph. Eur. 2.5.12, endotoxin below 0.25 EU/mg by Ph. Eur. 2.6.14, and reconstituted solution pH of 6.8–7.4 by Ph. Eur. 2.2.3. Binding activity against the manufacturer’s reference antigen panel is specified at ≥ 95% of the working reference. Each batch is released under process validation consistent with ISO 13485:2016 clause 7.5.2 and is accompanied by a certificate of analysis containing lot-specific values for colloidal gold particle size, residual moisture, endotoxin, and antigen-binding activity.

When the Freeze-Dried Matrix Is Compressed Into Tablets or Filled Into Capsules

Tablet formulations containing 0.5% w/w of VetADG-1024 and silicified microcrystalline cellulose have been processed on an 8-station rotary press at 25 rpm with compression force maintained between 6 and 8 kN. Under these conditions, tablet hardness is typically 60–80 N, and disintegration in 0.1 M phosphate-buffered saline at 37°C is complete within 5 minutes. Batch records indicate that capping incidence increases beyond 3% when the granule bulk density falls below 0.40 g/mL. Roller compaction with a 1.0 mm screen is therefore used to obtain a granule density of 0.52–0.58 g/mL before compression. Magnesium stearate is limited to ≤ 0.25% w/w because higher concentrations have been associated with delayed visual signal development in dissolution-based antigen capture tests.

For capsule filling on dosator-type equipment, the powder is blended to a bulk density of 0.45–0.60 g/mL and a particle size D90 ≤ 75 µm, measured by laser diffraction according to ISO 13320:2020. When D90 exceeds 75 µm, fill weight variability at 60,000 capsules/hour increases above ±3.0% relative standard deviation. Gelatin and hydroxypropyl methylcellulose capsules have shown equivalent compatibility at 25°C/60% RH for 30 days; published data for this specific configuration beyond 30 days is limited.

For injectable solutions, reconstitution in Water for Injection at 25°C produces a clear to slightly opalescent solution within 120 seconds. The solution is passed through a 0.22 µm PVDF membrane filter under aseptic conditions. Sterile-filtered aliquots maintain ≥ 90% binding activity for 24 hours at 2–8°C. A single freeze-thaw cycle at −20°C reduces binding activity by 12–18%. For injections, the product is not supplied as a terminal-sterilised finished dosage form; process validation under ISO 13485:2016 clause 7.5.2 or 21 CFR Part 820.75 is required at the formulator’s site. Use of divalent cation chelators above 1 mM is not recommended because colloidal gold aggregation can produce a false-negative signal.

What Are the Critical Specification Limits for Multi-Dosage Formulation?

These values function as multi-dosage threshold limits rather than finished-product specifications. The receiving facility is expected to verify blend uniformity, dosage-form-specific disintegration, dissolution, and container-closure parameters after incorporation. If the receiving formulation includes mineral premixes, copper sulfate pentahydrate at 150 mg/kg has been observed to reduce binding activity by 8% after 60 days at 40°C/75% RH. In that configuration, separate packaging or inert barrier co-granulation is required.

Powder, Granule, and Premix Mixing Parameters

Dry powder blends intended for top-dress or in-feed diagnostic use are diluted with lactose monohydrate or maltodextrin to a target inclusion rate of 0.05%–0.50% w/w. The active component is introduced by geometric dilution through a 630 µm screen. Final blend uniformity is considered acceptable when 10 stratified samples taken across a double-cone blender show a coefficient of variation ≤ 5.0%. Granulation by fluid-bed top spray using a 5% w/w hydroxypropyl methylcellulose solution maintained a particle size distribution between 150 and 710 µm and produced final granule moisture of 2.8%. High-shear granulation is not recommended because blade-tip speeds above 15 m/s can shear the conjugated gold surface and reduce antigen-binding activity.

For oral solution and water medication lines, the lyophilisate is reconstituted in purified water at 2–8°C and then mixed into bulk drinking water systems at a final concentration of 0.1–1.0 µg/mL. Solutions exposed to temperatures above 30°C for more than 4 hours show a decrease in optical density signal of 15%. Free chlorine above 0.5 ppm in the same water line oxidises the colloidal gold surface and produces false-negative readings. Do not autoclave or gamma-irradiate the product above 25 kGy; both terminal treatments denature the capture antibody and reduce binding activity below the release specification.

Compared with research-grade antigen-detection conjugates, VetADG-1024 is released against a panel of WOAH-reference positive and negative sera and includes endotoxin and residual moisture data. The product is not a final lateral-flow device; it differs from pre-cut cassette formats in that the formulator controls particle load, excipient ratio, and detection geometry. Against human diagnostic-grade conjugates, this veterinary grade API does not carry human clinical diagnostic performance claims and is not labelled for human specimen testing. Competitor veterinary reagents supplied as liquid suspensions often require continuous cold-chain logistics and have a higher baseline aggregation rate. The lyophilised format reduces this instability but introduces reconstitution handling and requires moisture-protective packaging at relative humidity above 60%.

Operational boundaries for unopened vials are storage at 2–8°C in the dark, use within 8 hours after reconstitution, and avoidance of oxidising agents, anionic detergents above 0.05% w/w, and divalent cation chelators above 1 mM. The product is incompatible with amine-based additives that can shift the reconstituted pH above 7.8 and promote colloidal aggregation. For premix applications containing organic acids, the blend should be tested for visual signal recovery after 48 hours because acidic microenvironments below pH 5.5 can destabilise the antibody conjugate.